The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis
C Corpechot, F Carrat, AM Bonnand, RE Poupon… - Hepatology, 2000 - journals.lww.com
Ursodeoxycholic acid (UDCA) is the only approved treatment for primary biliary cirrhosis
(PBC). However, the benefit from UDCA therapy on the progression of PBC from its early
stage towards extensive fibrosis and cirrhosis has not been clearly shown. The aim of this
study was to assess the effect of UDCA therapy on liver fibrosis progression in PBC. A
Markov model was used to analyze the progression rates between early and late histologic
stages in 103 patients with PBC enrolled in a randomized, double–blind, placebo–controlled …
(PBC). However, the benefit from UDCA therapy on the progression of PBC from its early
stage towards extensive fibrosis and cirrhosis has not been clearly shown. The aim of this
study was to assess the effect of UDCA therapy on liver fibrosis progression in PBC. A
Markov model was used to analyze the progression rates between early and late histologic
stages in 103 patients with PBC enrolled in a randomized, double–blind, placebo–controlled …